The effect of metformin on myocardial tolerance to ischemia-reperfusion in diabetes mellitus type 2 in experimental and clinical settings
https://doi.org/10.24884/1682-6655-2013-12-4-81-87
Abstract
The problem of cardiovascular complications of the diabetes mellitus (DM) draws close attention within the last decades. Patients with type 2 diabetes have 2-4 times greater risk for cardiovascular morbidity and mortality. Due to high prevalence of diabetes mellitus type 2, prevention of cardiovascular events in these patients is relevant. The goal of this study was to examine direct cardioprotective effect of antidiabetic drug metformin on ischemia-reperfusion injury in animal models and in patients. Two routs of metformin administration in acute ischemic injury were compared: continuous systemic before the ischemia and single local in the period of reperfusion. The cardioprotective phenotype appeared in local intracoronary administration to healthy animals. Clinical non-randomized observational study didn't reveal significant cardioprotective effect of metformin therapy before acute ischemic myocardial injury.
About the Authors
E. N. Kravchuk
V. A. Almazov Federal Center of Heart, Blood and Endocrinology
Russian Federation
Russian Federation
E. N. Grineva
V. A. Almazov Federal Center of Heart, Blood and Endocrinology
Russian Federation
Russian Federation
N. A. Smolina
V. A. Almazov Federal Center of Heart, Blood and Endocrinology
Russian Federation
Russian Federation
A. A. Khudiakov
V. A. Almazov Federal Center of Heart, Blood and Endocrinology
Russian Federation
Russian Federation
M. M. Galagudza
V. A. Almazov Federal Center of Heart, Blood and Endocrinology; I. P. Pavlov State Medical University
Russian Federation
Russian Federation
References
1. Демидова Т. Ю. Сосудистые осложнения сахарного диабета 2 типа за гранью гликемического контроля // Сахарный диабет. 2010. № 3. С. 111-116.
2. Минасян С. М. и др. Методика перфузии изолированного сердца крысы // Регионарное кровообращение и микроциркуляция. 2009. Т. 8. № 4. С. 54-59.
3. Галагудза М. М. и др. Устойчивость миокарда к ишемии и эффективность ишемического прекондиционирования при экспериментальном сахарном диабете // Росс. физиолог. журн. им. И. М. Сеченова. 2006. Т. 92. № 3. С. 284-291.
4. Петрищев Н. Н. и др. Роль свободных радикалов кислорода в механизмах локального и дистантного ишемического прекондиционирования миокарда // Вестник Росс. акад. мед. наук. 2006. № 8. С. 10-15.
5. Bagrov Y. Y. et al. Endogenous sodium pump inhibitors, diabetes mellitus and preeclampsia Preliminary observations and a hypothesis // Pathophysiology. 2007. Vol. 14. № 3-4. P. 147-151.
6. Bhamra G. S. et al. Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening // Basic Res. Cardiol. 2008. Vol. 103. № 3. P. 274-284.
7. Calvert J. W. et al. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling // Diabetes. 2008. Vol. 57. P. 696-705.
8. Davis B. J. et al. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase // Diabetes. 2006. Vol. 55. № 2. P. 496-505.
9. El Messaoudi S. et al. Metformin therapy in diabetes: the role of cardioprotection // Curr. Atheroscler. Rep. 2013. Vol. 15. № 4. P. 314.
10. Haffner S. M. et al. Mortality from coronary artery disease in subject with type 2 diabetes and nondiabetic subjects with and without myocardial infarction // N. Engl. J. Med. 1998. Vol. 339. P 229-234.
11. Kristiansen S. B. et al. Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes // Diabetologia. 2004. Vol. 47. № 10. P. 1716-1721.
12. Legtenberg R. J. et al. Metformin improves cardiac functional recovery after ischemia in rats // Horm. Metab. Res. 2002. Vol. 34. P. 182-185.
13. Lexis C. P. et al. Metformin in non-diabetic patients presenting with ST elevation myocardial infarction: rationale and design of the glycometabolic intervention as adjunct to primary percutaneous intervention in ST elevation myocardial infarction (GIPS)-III trial // Cardiovasc. Drugs Ther. 2012. Vol. 26. № 5. P. 417-426.
14. Paiva M. et al. Metformin prevents myocardial reperfusion injury by activating the adenosine receptor // J. Cardiovasc. Pharmacol. 2009. Vol. 53. № 5. P 373-378.
15. Paiva M. A. et al. Transitory activation of AMPK at reperfusion protects the ischaemic-reperfused rat myocardium against infarction // Cardiovasc. Drugs Ther. 2010. V. 24. P. 25-32.
16. Singh M. et al. Clinical and angiographic predictors of restenosis after percutaneous coronary intervention: insights from the Prevention of Restenosis With Tranilast and Its Outcomes (PRESTO) trial // Circulation. 2004. Vol. 109. № 22. P. 2727-2731.
17. Sobel B. E. et al. Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial // Circulation. 2011. Vol. 124. № 6. P. 695-703.
18. Solskov L. et al. Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24 h after administration // Basic Clin. Pharmacol. Toxicol. 2008. Vol. 103. P. 82-87.
19. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) // Lancet. 1998. Vol. 352. P. 854-865.
20. Wilcock C., Bailey C. J. Accumulation of metformin by tissues of the normal and diabetic mouse // Xenobiotica. 1994. Vol. 24. № 1. P. 49-57.
21. Zhao J. L. et al. Chronic pretreatment of metformin is associated with the reduction of the no-reflow phenomenon in patients with diabetes mellitus after primary angioplasty for acute myocardial infarction // Cardiovasc. Ther. 2013. V.ol 31. № 1. P. 60-64.
Review
For citations:
Kravchuk E.N., Grineva E.N., Smolina N.A., Khudiakov A.A., Galagudza M.M. The effect of metformin on myocardial tolerance to ischemia-reperfusion in diabetes mellitus type 2 in experimental and clinical settings. Regional blood circulation and microcirculation. 2013;12(4):81-87. (In Russ.) https://doi.org/10.24884/1682-6655-2013-12-4-81-87
Views:
440
Email this article 
